



Bristol-Myers Squibb Company  
Patent Department

RECEIVED  
CENTRAL FAX CENTER

JUN 7 2005

**FACSIMILE TRANSMITTAL SHEET**

**TO:** USPTO  
**FAX NO.:** 703-872-9306  
cc: Examiner Swope 571-273-0943  
**FROM:** Stephen C. D'Amico  
**TELEPHONE NO.:** (609) 252-5289  
**FACSIMILE NO.:** (609) 252-4526  
**DATE:** June 7, 2005  
**RE:** Our File No.: D0072 NP  
Serial No.: 10/029,345

**Number of Pages:** 128 (including cover sheet)

**Please find attached a copy of the Amendment Under 37 CFR §1.312.**

If you do not receive a complete fax, please contact Joyce Whitlow  
609-252-3597

*This document contains privileged client-attorney communications. The information is intended to be for the use of the addressee only. If you are not the addressee, note that any disclosure, copy, distribution or use of the contents of this document is prohibited. If you have received this message in error, please notify the sender of the error and delete the message. Thank you.*

JUN. 7. 2005 8:17AM

BMS PATENT DEPT

RECEIVED  
CENTRAL FAX CENTER

NO. 3861 P. 2

CASE D0072 NP

JUN 07 2005

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Stephen C. D'Amico  
Type or print name

  
Signature

June 7, 2005  
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1652

JACKSON ET AL.

Examiner: SWOPE, SHERIDAN

APPLICATION NO: 10/029,345

FILED: DECEMBER 20, 2001

FOR: POLYNUCLEOTIDES ENCODING THE NOVEL HUMAN  
PHOSPHATASE, RET31, AND VARIANTS THEREOF

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

AMENDMENT UNDER 37 CFR §1.312

Sir:

This paper is being filed in response to the Notice of Allowance mailed March 17, 2005. Applicants have received and reviewed the Notice of Allowance and the Examiner's Amendment in the above-referenced application. Applicants respectfully request that the present amendment, filed pursuant to 37 C.F.R. §1.312, be entered prior to issuance of the above-identified application. Applicants respectfully request that the application be amended as follows.

Amendments to the Specification begin on page 2 of this paper.

Remarks begin on page 126 of this paper.